Menu
Innovation Observatory > Reports > Respiratory Disease and Thoracic Surgery

Results

Drugs

December 2017

Benralizumab for Chronic Obstructive Pulmonary Disease (COPD)

Benralizumab is a new drug being developed for the treatment of chronic obstructive pulmonary
disease. It is administered by injection under the skin and acts by targeting specific proteins that
causes the airway to narrow. If benralizumab is licensed for use in the UK, it could be a new treatment
option for patients with chronic obstructive pulmonary disease that may improve quality of life and
reduce the number of exacerbations.

Drugs

August 2017

Tralokinumab for severe, uncontrolled asthma

Asthma is a long-term condition that affects the lungs and breathing. People with asthma have symptoms such as coughing, wheezing, chest tightness and breathlessness. Some people have symptoms despite trying various treatments or may suffer from more sudden ‘asthma attacks’. Severe asthma attacks can lead to hospitalisation, and on rare occasions can be life threatening. …

Devices

March 2017

Nyxoah Genio™ System for obstructive sleep apnoea

The Nyxoah Genio™ system is a device to treat people with obstructive sleep apnoea (OSA) who are not suitable for continuous positive airway pressure (CPAP) therapy. OSA is a common sleep disorder where the walls of the throat relax and narrow during sleep, interrupting normal breathing. The Nyxoah Genio™ system consists of a device which …

Drugs

November 2016

Ivacaftor with tezacaftor for cystic fibrosis with a homozygous or heterozygous F508del CFTR mutation

Cystic fibrosis is a long-term condition which affects the lungs and digestive system. The lungs can become clogged with thick, sticky mucus, which can cause problems with breathing from a young age. Over many years,  the lungs become increasingly damaged and may eventually stop working properly. The damage gets worse over time and many people …

Drugs

September 2016

Molgramostim inhalation for autoimmune pulmonary alveolar proteinosis

Molgramostim inhalation is a new drug to treat autoimmune pulmonary alveolar proteinosis (PAP). Autoimmune PAP is a rare lung disease that causes a build-up of protein material in the air sacs of the lungs, making it difficult to breath. Molgramostim inhalation is breathed in and works by altering the body’s immune response, helping to prevent …

Drugs

August 2016

Mepolizumab (Nucala) for chronic obstructive pulmonary disease with eosinophilic bronchitis – add on therapy

Chronic obstructive pulmonary disease (sometimes called chronic bronchitis or emphysema) is a lung disease that causes difficulties in breathing, mostly due to narrowing of the airways. The main cause of chronic obstructive pulmonary disease is smoking. Symptoms of this disease include increased difficulty breathing when active, persistent cough, and frequent chest infections. Patients with chronic …

Drugs

August 2016

Anti-Pseudomonas aeruginosa IgY for pseudomonal infection in cystic fibrosis

Pseudomonas aeruginosa is a bacterium that can damage the lungs of patients with cystic fibrosis even more, it can be difficult to treat, and once it becomes well-established, it may never be properly cleared from the lung.Anti-Pseudomonas aeruginosa IgY is a new drug for the treatment of infection with Pseudomonas aeruginosa in patients with cystic …

Devices

July 2016

Neurally Adjusted Ventilatory Assist (NAVA)

Neurally Adjusted Ventilatory Assist (NAVA) is a respiratory monitoring and support device for neonatal and paediatric patients, developed by Maquet Getinge Group. NAVA is a mechanical ventilation method that is characterised by a proportional response to diaphragm electromyography (EMG), originating from centrally controlled phrenic nerve stimulation. The device consists of a single-patient use nasogastric feeding …

Reviews

June 2016

SUMMARY – Emerging technologies for the diagnosis, treatment and management of refractory asthma

The NIHR Horizon Scanning Research and Intelligence Centre has published a horizon scanning review about health technologies in development for patients with refractory asthma. Refractory asthma is a poorly understood, poorly defined, complex heterogeneous disease in which adequate asthma control cannot be achieved or sustained in a substantial proportion of patients. Refractory asthma encompasses a …

Reviews

June 2016

REVIEW – Emerging technologies for the diagnosis, treatment and management of refractory asthma

The NIHR Horizon Scanning Research and Intelligence Centre has published a horizon scanning review about health technologies in development for patients with refractory asthma. Refractory asthma is a poorly understood, poorly defined, complex heterogeneous disease in which adequate asthma control cannot be achieved or sustained in a substantial proportion of patients. Refractory asthma encompasses a …

Get Alerts